Skip to main content

Table 1 Demographic and clinical characteristics of the samples used in the EPIC array assay

From: Epigenome-wide association study of Alzheimer’s disease replicates 22 differentially methylated positions and 30 differentially methylated regions

Brain region STG IFG
Clinical diagnosis Cognitively normal Alzheimer’s disease p** Cognitively normal Alzheimer’s Disease p**
Sample size N = 60 N = 67 N = 57 N = 60
Age at death (year), mean (SD) 80.65 (6.94) 81.00 (7.09) 0.717 81.00 (6.63) 81.13 (6.40) 0.967
Sex, male n (%) 37 (61.7) 39 (58.2) 0.692 36 (63.2) 35 (58.3) 0.593
PMI (hour), Mean (SD) 3.24 (2.02) 3.06 (1.60) 0.837 3.25 (2.05) 3.15 (1.69) 0.846
Estimated NeuN+ (%) Mean (SD) 30.3 (13.1) 29.6 (11.3) 0.504 24.5 (12.3) 28.1 (9.9) 0.159
Estimated NeuN (%), Mean (SD) 68.6 (14.1) 69.3 (12.7) 0.570 69.0 (15.4) 64.1 (12.0) 0.095
NIA-Reagan criteria [72], n
 Criteria not met 59    56   
 Not AD 1    1   
 Low   2    2  
 Intermediate   16    17  
 High   49    41  
Semiquantitative measure of neuritic plaques CERAD score [73], n
 Criteria not met 6    6   
 Not AD 33    31   
 Possible AD 21    20   
 Probable AD   8    8  
 Definite AD   59    52  
Braak stage, n
 I 15    12   
 II 14 2   14 2  
 III 20 4   21 4  
 IV 11 12   10 13  
 V   28    21  
 VI   21    20  
APOE genotype, n*
 ε2/ε2 1 0   2 0  
 ε2/ε3 10 3   10 1  
 ε3/ε3 32 26   30 26  
 ε3/ε4 16 33   15 27  
 ε2/ε4 0 1   0 1  
 ε4/ε4 1 3   0 4  
  1. SD: standard deviation; STG: superior temporal gyrus (BA22); IFG: inferior frontal gyrus (BA44); PMI: postmortem interval; CERAD [73]: Consortium to Establish a Registry for Alzheimer’s Disease
  2. *1 STG and 1 IFG sample, respectively, has missing APOE genotype
  3. **Wilcoxon rank-sum test for continuous variables; Chi-squared test for categorical variables